SCHEMBL19994458

SCHEMBL19994458

NNC(=O)CCC(c1ccccc1)N1C(=O)C=CC1=O

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 1/20 0.45
L3MBTL1 Q9Y468 1/20 0.43
CYP1A2 P05177 1/20 0.41
CYP3A4 P08684 1/20 0.41
CYP2D6 P10635 1/20 0.41
CYP2C19 P33261 1/20 0.41
CTSD P07339 1/20 0.39
KMT2A Q03164 1/20 0.39
SLC1A2 P43004 1/20 0.36
SLC1A1 P43005 1/20 0.36
BCAT2 O15382 1/20 0.36
KDM4E B2RXH2 1/20 0.35
MAPT P10636 1/20 0.35
EPHX2 P34913 1/20 0.35
SLC6A4 P31645 2/20 0.34
SLC6A2 P23975 1/20 0.34
LTA4H P09960 1/20 0.34
HDAC3 O15379 1/20 0.34
HDAC4 P56524 1/20 0.34
HDAC1 Q13547 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1608836 0.83 ALDH1A1 (0.46) L3MBTL1CYP1A2CYP3A4CYP2D6CYP2C19
SCHEMBL28786000 0.73 MGLL (0.38) L3MBTL1KMT2ASLC6A4SLC6A2
SCHEMBL10973243 0.73 KMT2A (0.47) L3MBTL1CYP1A2CYP2C19KMT2AKDM4E
SCHEMBL721638 0.73 KMT2A (0.37) L3MBTL1KMT2ASLC1A2MAPT
SCHEMBL29032349 0.72 L3MBTL1 (0.50) LMNAL3MBTL1CYP1A2CYP3A4CYP2D6
SCHEMBL3046367 0.72 CTSD (0.40) LMNAL3MBTL1CYP1A2CYP3A4CYP2D6
SCHEMBL28286235 0.70 LMNA (0.41) LMNAKMT2AMAPTSLC6A4SLC6A2
SCHEMBL9702157 0.69 CTSD (0.50) LMNAL3MBTL1CYP1A2CYP3A4CYP2D6
SCHEMBL9562580 0.68 MGLL (0.46) LMNAKMT2AMAPT
SCHEMBL8871482 0.68 ALDH1A1 (0.41) LMNAL3MBTL1CYP1A2CYP3A4CYP2D6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3515476-A1 FUSION COMPRISING A CELL PENETRATING PEPTIDE, A MULTI EPITOPE AND A TLR PEPTIDE AGONIST FOR TREATMENT OF CANCER Amal Therapeutics SA (CH) 2019-07-31 EP disclosed
WO-2018055060-A1 FUSION COMPRISING A CELL PENETRATING PEPTIDE, A MULTI EPITOPE AND A TLR PEPTIDE AGONIST FOR TREATMENT OF CANCER AMAL THERAPEUTICS SA (CH) 2018-03-29 WO disclosed